PFMU
BOLT icon

Privium Fund Management (UK)’s Bolt Biotherapeutics BOLT Stock Holding History

Privium Fund Management (UK)’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,826
Closed -$130K – 95
2023
Q4 		$130K Hold
5,826
– – 0.09% 71
2023
Q3 		$121K Hold
5,826
– – 0.09% 68
2023
Q2 		$148K Hold
5,826
– – 0.12% 64
2023
Q1 		$150K Hold
5,826
– – 0.12% 58
2022
Q4 		$151K Hold
5,826
– – 0.12% 46
2022
Q3 		$172K Buy
+5,826
New +$241K 0.22% 47

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Privium Fund Management (UK)'s BOLT Position: Q1 2024 in Review

Privium Fund Management (UK) sold out of Bolt Biotherapeutics (BOLT) in Q1 2024, closing a stake of 5,826 shares — an estimated $130K sold.

Privium Fund Management (UK) first reported a position in BOLT in Q3 2022 and held it in 6 quarters. The position peaked at $172K in Q3 2022. 37 funds tracked by Wall St. Rank hold BOLT as of Q1 2024.

  • Privium Fund Management (UK) reported no remaining Bolt Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Privium Fund Management (UK) sold 5,826 Bolt Biotherapeutics shares in Q1 2024, an estimated $130K.
  • Privium Fund Management (UK) first reported a position in Bolt Biotherapeutics in Q3 2022 and held it in 6 quarters.
  • Privium Fund Management (UK)'s Bolt Biotherapeutics position peaked at $172K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2024.

Based on Privium Fund Management (UK)'s 13F filing for Q1 2024, filed 29 Apr 2024.